Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 19/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 12/20 | 0.90 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8286906 | 0.95 | DRD2 (1.00) | DRD3DRD4DRD2SIGMAR1 | |
| SCHEMBL6985952 | 0.95 | DRD3 (1.00) | DRD3DRD4DRD2SIGMAR1 | |
| SCHEMBL6982595 | 0.92 | DRD3 (1.00) | DRD3DRD4DRD2SIGMAR1 | |
| SCHEMBL6984294 | 0.87 | DRD3 (1.00) | DRD3DRD4DRD2 | |
| SCHEMBL6984226 | 0.87 | DRD3 (1.00) | DRD3DRD4DRD2 | |
| SCHEMBL6985049 | 0.87 | DRD3 (1.00) | DRD3DRD4DRD2SIGMAR1 | |
| SCHEMBL13637989 | 0.86 | DRD2 (0.84) | DRD3DRD4DRD2SIGMAR1 | |
| SCHEMBL6981463 | 0.86 | DRD3 (1.00) | DRD3DRD4DRD2SIGMAR1 | |
| SCHEMBL6985375 | 0.85 | DRD3 (1.00) | DRD3DRD4DRD2 | |
| SCHEMBL6986108 | 0.84 | DRD3 (1.00) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751939-B9 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2003-01-02 | — | — | EP | claimed |
| EP-0751939-B1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2002-06-12 | — | — | EP | claimed |
| EP-0751939-A1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-01-08 | — | — | EP | claimed |
| WO-1995025727-A1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1995-09-28 | — | — | WO | claimed |
| US-5395835-A | Antipsychotic agents | WARNER-LAMBERT COMPANY (US) | 1995-03-07 | — | — | US | claimed |
| EP-0751939-B9 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020156050-A1 | Carboxamine compounds, methods and compositions for inhibiting PARP activity | GUILFORD PHARMACEUTICALS INC. | 2002-10-24 | — | — | US | disclosed |
| EP-0751939-B1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6395749-B1 | Carboxamide compounds, methods, and compositions for inhibiting PARP activity | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-0751939-A1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995025727-A1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1995-09-28 | — | — | WO | disclosed |
| US-5395835-A | Antipsychotic agents | WARNER-LAMBERT COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156050-A1 | Carboxamine compounds, methods and compositions for inhibiting PARP activity | PARP1, PARP3, PARP4 | DRD3 1715/4885DRD4 1437/4885DRD2 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.